10:37 AM EDT, 03/15/2024 (MT Newswires) -- BioXcel Therapeutics ( BTAI ) said Friday that the European Patent Office granted the company a patent that covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.

The patent covers various dosage forms, including films like BXCL501, wafers, and tablets. These forms contain dexmedetomidine doses from 3 micrograms to 100 micrograms, the company said.

The company added that the new patent aligns with its focus on expanding geographic coverage for BXCL501 into Europe along with the US and Japan.

Shares of BioXcel Therapeutics ( BTAI ) were more than 6% down in recent trading activity.

Price: 2.69, Change: -0.18, Percent Change: -6.45